Virtual screening for finding inhibitor against the main protease of SARS-Cov-2 from the FDA-approved drugs database

Xiaogang Liu, Shiye Wu, Zitong Zhu, Ying Wang, Binquan Gou*

*此作品的通讯作者

科研成果: 书/报告/会议事项章节会议稿件同行评审

摘要

At the end of 2019,a new coronavirus suddenly broke out all over the world.To date, there is still no targeted medicine available for the treatment of this disease. Vaccineis essential for controlling the epidemicofSARS-CoV-2. But the effective ofvaccine was reduced because of the SARS-CoV-2constant mutation. It is gratifying that scientistuncover theinfection mechanisms of the SARS-CoV-2. The main protease of SARS-CoV-2 is highly conserved and plays an important role of the life cycle of virus. Therefore, we executed virtual screening on the FDA-approved database and hoped to find a potential candidate against the main protease. As a result, we obtained eight available active compounds derived from the database through molecular dynamics simulations. As antiviral treatment candidates, the drugs can also be used to clinical emergencies.

源语言英语
主期刊名International Conference on Biomedical and Intelligent Systems, IC-BIS 2022
编辑Ahmed El-Hashash
出版商SPIE
ISBN(电子版)9781510660212
DOI
出版状态已出版 - 2022
活动2022 International Conference on Biomedical and Intelligent Systems, IC-BIS 2022 - Chengdu, 中国
期限: 24 6月 202226 6月 2022

出版系列

姓名Proceedings of SPIE - The International Society for Optical Engineering
12458
ISSN(印刷版)0277-786X
ISSN(电子版)1996-756X

会议

会议2022 International Conference on Biomedical and Intelligent Systems, IC-BIS 2022
国家/地区中国
Chengdu
时期24/06/2226/06/22

指纹

探究 'Virtual screening for finding inhibitor against the main protease of SARS-Cov-2 from the FDA-approved drugs database' 的科研主题。它们共同构成独一无二的指纹。

引用此